CSF3 and acute myeloid leukemia: These results, together with other studies (69, 82, 91), suggest that haplo-SCT based on immune tolerance induced by G-CSF and ATG is a valid alternative as a postremission treatment of intermediate- or high-risk AML patients in CR1 lacking an identical donor.